Project description:We investigated the functional gene expression changes associated with temperature stress in two psychrophilic sea ice bacteria, Polaribacter sp. ALD9 and Shewanella sp. ALD11.
Project description:A xylan ulitization locus in Polaribacter sp. Q13, named XUL-Q13, was predicted to be involved in mixed-linkage xylan utilization. To support this, Polaribacter sp. Q13 was cultivated separately in triplicates on mixed-linkage xylan (MX_1, MX_2, MX_3), xylose (X_1, X_2, X_3) and glucose (G_1, G_2, G_3) and their proteomes were analyzed. In addition, the proteome of the resting cells (T0) was also analyzed.
Project description:Investigation of gene expression level changes in Gordonia sp. KTR9 and Gordonia sp. KTR9 mutant GlnR upon exposure to high and low nitrogen conditions The Gordonia sp. KTR9 strain used in this study has been previously described by Thompson KT, Crocker FH, Fredrickson HL.2005. Mineralization of the cyclic nitramine explosive hexahydro-1,3,5-trinitro-1,3,5-triazine by Gordonia and Williamsia spp. Appl Environ Microbiol. 2005 Dec;71(12):8265-72.
Project description:Investigation of gene expression level changes in Gordonia sp. KTR9 upon exposure to RDX and Nitrogen Limitation, compared to controls with no RDX. The Gordonia sp. KTR9 strain used in this study has been previously described by Thompson KT, Crocker FH, Fredrickson HL.2005. Mineralization of the cyclic nitramine explosive hexahydro-1,3,5-trinitro-1,3,5-triazine by Gordonia and Williamsia spp. Appl Environ Microbiol. 2005 Dec;71(12):8265-72.
Project description:Investigation of gene expression level changes in Gordonia sp. KTR9 and Gordonia sp. KTR9 mutant GlnR upon exposure to high and low nitrogen conditions The Gordonia sp. KTR9 strain used in this study has been previously described by Thompson KT, Crocker FH, Fredrickson HL.2005. Mineralization of the cyclic nitramine explosive hexahydro-1,3,5-trinitro-1,3,5-triazine by Gordonia and Williamsia spp. Appl Environ Microbiol. 2005 Dec;71(12):8265-72. A 12 x 135K array study using total RNA recovered from triplicate cultures of KTR9 exposed to high nitrogen conditions, triplicate cultures of KTR9 exposed to low nitrogen conditions, triplicate cultures of KTR9 mutant GlnR exposed to high nitrogen conditions, triplicate cultures of KTR9 mutant GlnR exposed to low nitrogen conditions.
Project description:Investigation of gene expression level changes in Gordonia sp. KTR9 upon exposure to RDX and Nitrogen Limitation, compared to controls with no RDX. The Gordonia sp. KTR9 strain used in this study has been previously described by Thompson KT, Crocker FH, Fredrickson HL.2005. Mineralization of the cyclic nitramine explosive hexahydro-1,3,5-trinitro-1,3,5-triazine by Gordonia and Williamsia spp. Appl Environ Microbiol. 2005 Dec;71(12):8265-72. A 12 x 135K array study using total RNA recovered from triplicate cultures of KTR9 exposed to RDX, triplicate cultures of KTR9 exposed to RDX and high nitrogen conditions, triplicate cultures of KTR9 exposed to low nitrogen, and triplicate cultures of controls exposed to high nitrogen.
Project description:Background: Plasmapheresis/rituximab-based desensitization therapy has successfully reduced anti-ABO antibody levels and suppressed antibody-mediated rejection (AMR) in ABO-incompatible (ABOi) kidney transplantation (KT). However, high titers of anti-ABO antibodies in some patients are refractory to standard desensitization, leading to loss of KT opportunities or AMR. Methods: Eculizumab-based desensitization was used to rescue high-titer ABOi KT patients refractory to plasmapheresis/rituximab-based desensitization. Results: The initial titers of anti-ABO IgG antibodies in the two patients were 1:512 and >1:1024; the final pre-transplant titers after desensitization were 1:128 and 1:64. Both patients received eculizumab from the day of KT to two or four weeks post-KT and maintained stable renal function up to one-year post-transplantation without overt infectious complications, despite early episodes of suspicious AMR or borderline T cell-mediated rejection. Molecular phenotype analysis of allograft biopsies using the Banff Human Organ Transplant gene panel revealed that gene expression patterns in the ABOi KT with eculizumab group overlapped with those in the ABOi KT with AMR group more than in the ABOi KT without AMR group, except for complement pathway-related gene expression. Anti-ABO antibody titers decreased to low levels 1–3 months post-transplant in the eculizumab group in parallel with decreasing anti-B-specific B cells at this time point. Conclusions: Short-term eculizumab-based desensitization therapy is promising for rescuing ABOi KT recipients with unacceptably high anti-ABO antibody titers refractory to plasmapheresis-based desensitization therapy.
